## **REMARKS**

Applicants have amended to specification to reflect sequences disclosed in the figure. To that end, Applicants wish to provide the Examiner with an amended sequence listings, adding Sequences 26 – 33, which are the Sequences cited in Figure 3. A Statement Under 37 CFR1.821 (a)1 and (a)(2) is being submitted along with paper copy and CRF of the Sequence Listing.

The Commissioner is authorized to charge any fees associated with this communication to Deposit Account No. 15-0615 for any matter in connection with this response, including any fee for extension of time, which may be required.

Respectfully submitted,

Date: 8 30 05

Gregory Giotta

ONYX Pharmaceuticals, Inc. 2100 Powell Street 12<sup>th</sup> floor
Emeryville, CA 94608
Telephone (510) 597-6503
Facsimile (510) 597-6610